20-F: Immatics Advances PRAME Therapies, Secures Funding

Immatics N.V. reports significant progress in its PRAME-directed immunotherapy pipeline, including advancing lead cell therapy anzu-cel into Phase 3, alongside a recent $107.2 million public offering.

Summary

• Immatics N.V. is a clinical-stage biopharmaceutical company focused on PRAME-directed immunotherapies for cancer, utilizing TCR-based cell therapy and bispecific modalities.
• The company's lead PRAME cell therapy, anzu-cel (IMA203), is in a registration-enabling Phase 3 trial (SUPRAME) for advanced cutaneous melanoma and a Phase 2 trial for metastatic uveal melanoma.
• Anzu-cel has demonstrated a confirmed objective response rate (cORR) of 56% (18/32) in Phase 1b melanoma patients, with 42% (14/33) achieving deep responses (>=50% tumor size reduction).
• Median duration of response (mDOR) for anzu-cel was 12.1 months, median progression-free survival (mPFS) was 6.1 months, and median overall survival (mOS) was 15.9 months.
• IMA203CD8, a second-generation PRAME cell therapy, showed an encouraging early clinical cORR of 36% (23/64) across multiple advanced solid tumors in its Phase 1a dose escalation, with deep and durable responses up to 3+ years.
• IMA402, an off-the-shelf PRAME bispecific, demonstrated a 30% cORR (6/20) at its recommended Phase 2 dose (RP2D) range in various indications, including melanoma and ovarian carcinoma.
• The company reported an accumulated consolidated loss of €786.0 million as of December 31, 2025.
• Cash and cash equivalents increased to €345.9 million as of December 31, 2025, from €236.7 million in 2024.
• Revenue from collaboration agreements decreased to €48.3 million in 2025 from €155.8 million in 2024, primarily due to lower project progress and termination of certain agreements.
• Research and development expenses increased to €183.8 million in 2025 from €148.1 million in 2024, driven by increased clinical trial activities for anzu-cel and IMA402.
• General and administrative expenses increased to €51.2 million in 2025 from €46.4 million in 2024, mainly due to commercialization preparation for anzu-cel and headcount growth.
• A public offering on December 8, 2025, raised net proceeds of €100.2 million from the sale of 12,500,000 ordinary shares at $10.00 per share.
• The company remediated a material weakness in internal control over financial reporting related to deferred tax assets and liabilities during 2025.
• The company believes it was a Passive Foreign Investment Company (PFIC) for the 2025 tax year and may continue to be so, which could have adverse U.S. federal income tax consequences for U.S. investors.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing with cautious optimism. While the clinical data for the PRAME franchise is highly promising and the company successfully raised capital, the significant increase in net losses and cash burn, coupled with reduced collaboration revenue, indicates ongoing financial challenges typical of a clinical-stage biotech. The PFIC status is also a notable negative for U.S. investors.

Positives

• Anzu-cel (IMA203) achieved a compelling confirmed objective response rate (cORR) of 56% in Phase 1b advanced melanoma patients, with 42% showing deep responses (>=50% tumor reduction).
• Anzu-cel demonstrated durable responses with a median duration of response (mDOR) of 12.1 months, median progression-free survival (mPFS) of 6.1 months, and median overall survival (mOS) of 15.9 months.
• Anzu-cel received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for multiple PRAME-expressing cancers, including cutaneous and uveal melanoma, and Orphan Drug Designation for both indications.
• The proprietary manufacturing process for anzu-cel boasts a fast turnaround time of ~2 weeks and a ~95% manufacturing success rate, supporting rapid and reliable patient delivery.
• IMA203CD8, the second-generation PRAME cell therapy, showed encouraging early clinical anti-tumor activity with a 36% cORR across multiple advanced solid tumors, including three complete responses.
• IMA402 PRAME bispecific demonstrated a 30% cORR at its RP2D range, with all 6 confirmed objective responses ongoing as of the data cutoff, including two complete metabolic responses.
• The company successfully raised €100.2 million in net proceeds from a public offering in December 2025, strengthening its capital position.
• A research allowance of €4.6 million was recognized as other income under the German Research Allowance Act for eligible R&D activities.
• The company remediated a previously identified material weakness in internal control over financial reporting during 2025.

Negatives

• The company has a history of operating losses and expects to continue incurring losses for the foreseeable future, with accumulated consolidated losses of €786.0 million as of December 31, 2025.
• Revenue from collaboration agreements significantly decreased by €107.5 million in 2025 compared to 2024, primarily due to lower project progress and termination of agreements with BMS and Genmab.
• Research and development expenses increased by €35.8 million in 2025, indicating continued high cash burn for development activities.
• Other financial expenses increased substantially from €1.3 million in 2024 to €36.7 million in 2025, mainly due to higher unrealized foreign exchange losses.
• The company believes it was a Passive Foreign Investment Company (PFIC) for the 2025 tax year and may be a PFIC for future taxable years, which could result in adverse U.S. federal income tax consequences for U.S. investors.
• The company's public warrants expired on July 1, 2025, without any being exercised, indicating that the market price of the ordinary shares was below the exercise price of $11.50.

Risks

• The company has a history of operating losses and expects to continue incurring losses for the foreseeable future, potentially never achieving or sustaining profitability.
• Clinical trials are expensive, time-consuming, and difficult to design and implement, with potential for delays or termination at any stage due to negative preclinical data, regulatory clearance issues, patient recruitment challenges, safety issues, or manufacturing problems.
• Product candidates may cause undesirable side effects or have other properties that could delay or prevent development, regulatory approval, or limit commercial potential, especially given their novel nature as cell therapies and bispecifics.
• Changes in regulatory requirements, particularly for novel cell and gene therapies, could result in delays, discontinuation of development, or unexpected costs.
• Dependence on third parties for preclinical studies, clinical trials, and manufacturing introduces risks related to performance, compliance, and supply chain disruptions.
• The company faces substantial competition from large pharmaceutical and biotechnology companies, academic institutions, and other research organizations with greater resources.
• Commercial success depends on significant market acceptance among physicians, patients, and payors, which may be challenging given existing treatments and other novel product candidates.
• Coverage and reimbursement for product candidates may be limited or unavailable, making it difficult to sell products profitably, especially for expensive cell therapies and combination treatments.
• Exposure to fluctuations in foreign exchange rates, particularly between the euro and U.S. dollar, can adversely affect business, results of operations, and financial condition.
• The use of net operating loss carryforwards may be limited by tax laws (e.g., U.S. Sections 382 and 383) or non-acceptance by tax authorities, impacting future profitability.
• Intellectual property protection may be inadequate, with risks of patent challenges, infringement claims, and unauthorized disclosure of trade secrets.
• Past and continued use of AI-powered solutions (e.g., XPRESIDENT, XCUBE) could lead to operational or reputational damage, competitive harm, and additional costs due to design flaws, biased data, or evolving regulations.
• The company is highly dependent on key personnel, and the inability to attract and retain qualified individuals could harm business strategy and product development.
• Operating internationally exposes the company to economic, political, regulatory, and other risks, including differing regulatory requirements, exchange controls, and geopolitical events.
• Failure to maintain an effective system of internal control over financial reporting could lead to inaccurate financial reports or fraud, despite remediation efforts for past material weaknesses.
• The market price of the company's securities has been and may continue to be volatile due to various factors beyond its control, including clinical trial results, regulatory actions, and market conditions.
• As a Dutch public company, the rights of shareholders may differ from those in U.S. jurisdictions, and certain provisions of the articles of association or Dutch corporate law might deter acquisition bids.
• The company may become taxable in a jurisdiction other than Germany, potentially increasing tax payments or liabilities.
• If the company ever pays dividends, it may need to withhold tax in both Germany and the Netherlands, and U.S. investors may face adverse U.S. federal income tax consequences if the company is a PFIC.

Future Outlook

The company expects to continue incurring significant operating losses as it advances its product candidates through clinical development and prepares for potential commercialization. It plans to refine its commercial and regulatory strategy for anzu-cel beyond the U.S., starting with EU5 countries. The company believes its existing cash and financial assets are sufficient to fund operations for at least the next 12 months but may seek additional capital for strategic investments or other reasons. Future funding requirements are highly dependent on clinical trial progress, regulatory approvals, and commercial success.

Management Comments

• "Our mission is to make a meaningful impact on the lives of patients with cancer and high unmet medical needs by delivering novel, PRAME-directed immunotherapies that provide tangible clinical benefits."
• "We strive to become an industry-leading, fully integrated global biopharmaceutical company engaged in developing, manufacturing and commercializing PRAME immunotherapies for the benefit of patients with cancer, our shareholders, our employees and our partners."
• "We believe PRAME is one of the most promising and prevalent clinically validated solid tumor targets known to date."
• "We believe currently that our cell therapy-based treatments are likely to be best positioned initially for monotherapy settings in the second-line and later, where the medical need is highest due to a lack of alternative treatment options."
• "We believe our proprietary in-house manufacturing and good manufacturing practices (GMP) facility as well as in-house QC testing enable us to better control the manufacturing process, shorten the turnaround time, ensure a high manufacturing success rate and quality of product, and to realize potential cost efficiencies, including manufacturing capacity optimization through scalability to deliver a competitive and profitable commercial cell therapy product."
• "We believe the early proof-of-concept data in ovarian carcinoma support this strategy [for IMA203CD8 in tumor-agnostic setting]."
• "We are well positioned to assess the synergistic potential of combining two different bispecifics, IMA402 targeting PRAME and IMA401 targeting MAGEA4/8, with and without a checkpoint inhibitor."
• "We believe that we have sufficient capital resources to fund our operations through at least the next 12 months."

Industry Context

StockSavvy.ai notes that Immatics N.V. is positioning itself as a leader in the rapidly evolving immuno-oncology field, particularly with its focus on PRAME, a target expressed in over 50 cancers. The company's dual modality approach (TCR T-cell therapy and bispecifics) aims to address different patient populations and treatment lines, a strategy that could provide a competitive edge against companies focusing on single modalities like Iovance (TILs) or Immunocore (TCR bispecifics). The reported clinical response rates for anzu-cel and IMA203CD8, coupled with RMAT and Orphan Drug designations, suggest promising efficacy in heavily pretreated patient populations, which is critical in a competitive landscape where many therapies target similar advanced cancer indications. The collaboration with Moderna for mRNA-based TCERs also highlights a trend towards leveraging diverse technologies to enhance therapeutic potential and expand market reach.

Comparison to Industry Standards

• Anzu-cel's cORR of 56% in Phase 1b advanced melanoma is competitive, especially in heavily pretreated patients, compared to other novel cell therapies. For example, Iovance's TIL therapy (lifileucel) showed an objective response rate of 31% in post-anti-PD1 melanoma patients in its C-144-01 trial, suggesting anzu-cel's efficacy is favorable.
• The median duration of response (mDOR) of 12.1 months for anzu-cel is a strong indicator of durability, which is a key differentiator for cell therapies. This compares favorably to some approved checkpoint inhibitors in later lines of therapy, which may have shorter mDORs in similar patient populations.
• The ~2-week manufacturing turnaround time and ~95% success rate for anzu-cel are highly competitive within the autologous cell therapy space, where manufacturing complexity and vein-to-vein time are critical challenges. This is significantly faster than some other autologous cell therapies, which can take 3-4 weeks or longer.
• IMA203CD8's early cORR of 36% across multiple solid tumors, including complete responses, is promising for a second-generation cell therapy, particularly in tumor types beyond melanoma that often present more complex microenvironments. This early data suggests potential for broader applicability compared to first-generation approaches.
• IMA402's 30% cORR for an off-the-shelf bispecific in later-line patients is notable, as bispecifics generally aim for lower but more consistent response rates than cell therapies, with the advantage of being off-the-shelf. This positions it well against other bispecific T-cell engagers in development, such as those from Immunocore or CDR-Life, which also target intracellular antigens.

Management Changes

Corporate Governance

Legal Proceedings

• As of the date of this Annual Report, the company does not believe it is party to any claim or litigation that would, individually or in the aggregate, be reasonably expected to have a material adverse effect on its business.

Related Party Transactions

• The company granted certain registration rights to securityholders, including ARYA Sciences Holdings, under an Investor Rights Agreement from the ARYA Merger, providing demand and piggy-back registration rights.
• Indemnification agreements were entered into with each executive officer and director, providing for procedures for indemnification and advancements of certain expenses and costs to the maximum extent permitted by Dutch law.
• Certain members of the Board (Michael G. Atieh, Adam Stone, Paul R. Carter, Mathias Hothum) were designated pursuant to agreements related to the ARYA Merger, and certain shareholders continue to have director nomination rights.
• Compensation of key management personnel (Executive Committee) included fixed, variable, and share-based compensation, totaling €13.6 million in 2025.
• Compensation for non-executive directors totaled €2.5 million in 2025, including fixed board compensation and share-based compensation expenses.
• In 2025, an additional aggregate of 561,000 service options to purchase ordinary shares were granted to other Immatics key management personnel who are members of the Executive Committee but not Directors.
• In January 2026, the company granted 1,055,080 Restricted Stock Units to employees, including executive officers.

Stakeholder Impact

• **Shareholders:** Dilution from recent and potential future equity offerings, potential adverse U.S. federal income tax consequences due to PFIC status, and reliance on future product commercialization for returns. However, clinical progress and capital raises provide funding for continued development.
• **Employees:** Increased headcount and personnel-related expenses reflect growth, and equity incentive plans aim to attract and retain talent. Management changes indicate strategic adjustments in leadership.
• **Customers (future):** Potential for novel PRAME-directed immunotherapies to address high unmet medical needs in various cancers, offering new treatment options.
• **Collaboration Partners:** Ongoing strategic collaborations (e.g., Moderna, BMS) provide non-dilutive capital and leverage synergistic capabilities, but terminations (e.g., Genmab, some BMS programs) can impact revenue and pipeline diversification.
• **Creditors:** Accumulated losses and continued cash burn indicate reliance on equity financing, but a strong cash position and recent capital raise provide near-term liquidity.

Next Steps

• Next data update from the Phase 1/2 trial for anzu-cel (IMA203) in cutaneous and uveal melanoma with ongoing follow-up: 2026.
• SUPRAME Phase 3 trial interim and final data analyses triggered: 2026.
• Biologics License Application (BLA) submission for anzu-cel: 1H 2027.
• Market launch of anzu-cel in the U.S. (assuming BLA approval): 2H 2027.
• Data update from ongoing Phase 1a trial for IMA203CD8, focusing on ovarian cancer at relevant doses, to be presented at a major medical conference: 1H 2026.
• Completion of dose escalation and determination of Recommended Phase 2 Dose (RP2D) for IMA203CD8: 2026.
• RP2D determination and clinical Phase 1 data update for IMA402 PRAME bispecific, focusing on melanoma and gynecologic cancers (monotherapy and combination with immune checkpoint inhibitor): 2H 2026.
• Initiation of IMA402/IMA401 combination trial in squamous non-small cell lung cancer (sqNSCLC): 2026.
• Presentation of updated Phase 1a data for IMA401 MAGEA4/8 bispecific at a major medical conference: 1H 2026.
• The company will conduct a Phase 1 clinical trial in collaboration with Moderna for a novel mRNA-based TCER product, with all associated costs reimbursed by Moderna.

Key Dates

Recommendation

Immatics N.V. presents a mixed financial picture with significant losses and increased cash burn in 2025, but this is largely offset by promising clinical data for its PRAME-directed therapies and a successful capital raise. The lead candidate, anzu-cel, is progressing to Phase 3 with strong early efficacy and durability, while next-generation therapies also show encouraging results. The company's proprietary technology platforms and manufacturing capabilities are competitive advantages. However, the substantial accumulated deficit, continued reliance on external financing, and the PFIC status for U.S. investors introduce considerable risk. The stock is a 'hold' for seasoned investors who recognize the high-risk, high-reward nature of clinical-stage biotechs, as the long-term potential is significant but contingent on successful clinical outcomes and regulatory approvals, which are inherently uncertain. The recent capital raise provides a runway, but further dilution or financing will likely be needed.

Keywords

PRAME, Immunotherapy, TCR-T cell therapy, Bispecifics, Anzu-cel, IMA203, IMA203CD8, IMA402, IMA401, Melanoma, Ovarian cancer, Solid tumors, Clinical trials, Oncology, Biopharmaceutical, SEC filing, 20-F, Nasdaq, Moderna, Bristol Myers Squibb, XPRESIDENT, XCEPTOR, GMP manufacturing, Capital raise, Financial results